1. Home
  2. EOLS vs EAD Comparison

EOLS vs EAD Comparison

Compare EOLS & EAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EOLS
  • EAD
  • Stock Information
  • Founded
  • EOLS 2012
  • EAD 2003
  • Country
  • EOLS United States
  • EAD United States
  • Employees
  • EOLS N/A
  • EAD N/A
  • Industry
  • EOLS Biotechnology: Pharmaceutical Preparations
  • EAD Finance/Investors Services
  • Sector
  • EOLS Health Care
  • EAD Finance
  • Exchange
  • EOLS Nasdaq
  • EAD Nasdaq
  • Market Cap
  • EOLS 444.0M
  • EAD 404.8M
  • IPO Year
  • EOLS 2018
  • EAD N/A
  • Fundamental
  • Price
  • EOLS $7.03
  • EAD $6.85
  • Analyst Decision
  • EOLS Strong Buy
  • EAD
  • Analyst Count
  • EOLS 4
  • EAD 0
  • Target Price
  • EOLS $21.25
  • EAD N/A
  • AVG Volume (30 Days)
  • EOLS 2.0M
  • EAD 178.9K
  • Earning Date
  • EOLS 11-05-2025
  • EAD 01-01-0001
  • Dividend Yield
  • EOLS N/A
  • EAD 8.91%
  • EPS Growth
  • EOLS N/A
  • EAD N/A
  • EPS
  • EOLS N/A
  • EAD N/A
  • Revenue
  • EOLS $285,823,000.00
  • EAD N/A
  • Revenue This Year
  • EOLS $13.39
  • EAD N/A
  • Revenue Next Year
  • EOLS $26.85
  • EAD N/A
  • P/E Ratio
  • EOLS N/A
  • EAD N/A
  • Revenue Growth
  • EOLS 15.10
  • EAD N/A
  • 52 Week Low
  • EOLS $5.71
  • EAD $5.69
  • 52 Week High
  • EOLS $17.12
  • EAD $6.81
  • Technical
  • Relative Strength Index (RSI)
  • EOLS 53.48
  • EAD 50.26
  • Support Level
  • EOLS $6.53
  • EAD $6.67
  • Resistance Level
  • EOLS $7.01
  • EAD $6.92
  • Average True Range (ATR)
  • EOLS 0.41
  • EAD 0.06
  • MACD
  • EOLS -0.01
  • EAD 0.00
  • Stochastic Oscillator
  • EOLS 45.53
  • EAD 64.15

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

About EAD Allspring Income Opportunities Fund

Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.

Share on Social Networks: